In line with previous studies involving T2DM patients without HF, our prospective multicenter trial using T2DM patients with HF showed that SGLT2 inhibitors were associated with improvements in LV diastolic functional parameters including E/e′, LAVI, and LVMI. The gene discussed is SLC5A2; the disease is hydrops fetalis.